Reach Us +1-217-403-9671
Cell Therapy Manufacturing Tools And Global Regulatory Environment | 8284
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Cell therapy manufacturing tools and global regulatory environment

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

Jiwen Zhang

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

C ell therapies are anticipated to be the next breakthrough to address unmet medical needs. Th ough use of cells as therapeutic agents such as bone marrow transplant has been in medical practice for decades, cell therapy regulati ons are relatively new, or emerging in most countries and regions, including the US and the EU. In this evolving regulatory environment, how cell therapy tools are regulated is not straight forward. Wave, a bioreactor intended for expansion of human cells in suspension, has been on the market in the US and Canada. Since cell therapy is regulated similarly as drugs or biologics in the US and Canada, Wave Bioreactor is regulated as manufacturing equipment but not a medical device, the same as for biologic ma nufacturing equipment. A Drug Master File for Wave has been fi led at the FDA and cross-referenced by INDs cleared to initiate clinical trials for testing investigational cell therapy products. While cell therapy development is advancing around the world, particularly in Asian Pacifi c countries, the demand of an automated, scalable bioreactor such as Wave for manufacturing cell therapy product has increased. However, due to unclear or evolving regulations in these countries, confusions arise on whether Wave bioreactor should be regulated as equipment or a medical device. As the author works with individual countries to map out regulatory pathway for Wave, it has become clear that a harmonized regulatory requirement for cell therapy products and cell therapy processing tools are critical to bring innovative cell therapies to patients in needs.
Jiwen Zhang received her Ph.D from the joint Physiology and Neurobiology program at Rutgers University and University of Medicine and Dentistry of New Jersey. Currently, she is a Regulatory Affairs Director for Strategic Initiative at GE Healthcare. Before joining GEHC, she had worked in pharmaceutical and biotech industry as a regulatory affairs professional developing biologics, small molecule drugs, and cell therapies in different therapeutic areas. Jiwen has taught RA courses at universities and given presentations at industry symposiums on drug development and regulatory strategies.